



# Australian Cardio- Oncology Registry

## **Annual Report 3: 2020-21**

## Contents

Summary.....	1
ACOR update.....	1
Welcome Ben! .....	1
Recruitment .....	2
Enrolments.....	2
Diagnosis.....	2
ACOR study enrolment process.....	2
Eligibility.....	2
Project expansion - 2021 onwards .....	3
Cardio-Oncology Clinics .....	3
Cardio-Oncology guidelines.....	3
Register your interest to be part of ACOR If you are interested or know someone who is interested in being a participating site please contact:.....	4
<b>ACOR National Coordinator via email at <a href="mailto:acor@mcri.edu.au">acor@mcri.edu.au</a>.....</b>	<b>4</b>
<b>Or via telephone on: 03 9936 6033 .....</b>	<b>4</b>
<b>We look forward to hearing from you.....</b>	<b>4</b>

# Australian Cardio- Oncology Registry

## Summary

The Australian Cardio-Oncology Registry (ACOR) was created in 2018 to collect information about patients who have been exposed to cardiotoxic chemotherapies as part of their cancer treatment regimen. ACOR is a unique initiative to improve the cardiovascular health of paediatric, adolescent and young adult and adult cancer survivors. ACOR is a national study that includes 13 participating sites and will enrol 600 patients per year over a period of 3 years. This collaboration will address the following hypothesis and aims:

**Hypothesis:** The establishment of the registry and biobank will change the morbidity outcomes and ameliorate the burden of care on the health care system for paediatric and young adult patients with cardiovascular disease.

**Aim 1:** To expand Australia's first national cardio-oncology registry and biobank for paediatric, young adult and adult oncology patients that have been treated with cardiotoxic therapies.

**Aim 2:** To develop and implement national cardio-oncology guidelines and clinics, for the identification and management of cardiovascular disease in paediatric, adolescent/young adult and adult cancer survivors.

**Aim 3:** To include patient and patient families views through a Patient Advisory Group to improve patient care.

**Aim 4:** To determine (a) the cost and (b) short-term cost-effectiveness of the registry and cardio-oncology clinics, from a government and/or societal perspectives.

## ACOR update

### Welcome Ben!



We are pleased to welcome Ben Felmingham – who joined our team in October 2021. He is the Academic Lead Pharmacist and will be utilising his extensive experience and expertise in paediatric oncology pharmacy to lead the development of the cardio-oncology guidelines and to coordinate the cardio-oncology clinic at Royal Children's Hospital (Melbourne).

## Recruitment

### Enrolments

Enrolments into the registry were adversely affected by COVID-19 in 2020-21. To date, a total of 113 patients have been entered into the ACOR database. Currently, the following sites are enrolling patients into the study:

- The Royal Children's Hospital
- Monash Children's Hospital
- Peter MacCallum Cancer Centre
- Women's and Children's in Adelaide, SA
- Royal Hobart Hospital

The Royal Melbourne Hospital, Perth Children's Hospital, The Sydney Children's Network and the John Hunter Children's Hospital are approved for the study and can welcome patients into the registry. Further 2 sites (Chris O'Brien Lifehouse and Royal Prince Alfred Hospital) are in the process of getting research governance approval to commence recruitment.

### Diagnosis

The most common diagnosis is Acute Lymphoid Leukaemia (ALL) – 43% of diagnosis in the registry.

## ACOR study enrolment process

### Eligibility


Any patients with a diagnosis of cancer who is exposed (or previously has been exposed) to cardiac toxic therapies.

Cardiac toxic therapies includes radiotherapy, anthracyclines, VEGF inhibitors, proteasomal inhibitors, tyrosine kinase inhibitors, immunotherapy, cyclophosphamide.

AND

Consenting to being included on the registry and sub studies OR have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participants behalf.

## Project expansion - 2021 onwards



### Cardio-Oncology Clinics

In August 2021, we were privileged to receive funding from the National Health Foundation (NHF) Strategic Partnership grant to support the infrastructure required for 3 cardio-oncology hubs (clinics) of expertise nationally. The purpose of these hubs (clinics) is to deliver a centralised and standardised service to patients who have been identified to be at risk of developing cardiac dysfunction after exposure to cancer therapy. Each clinic will have a dedicated multi-specialty clinicians who will provide their expertise to optimise acute and long term cardiovascular health patient outcomes.

These hubs will be located in Victoria at the Royal Children's Hospital and in New South Wales at Chris O'Brien Lifehouse/ Royal Prince Alfred Hospital and Sydney Children's Hospital Network sites.

### Cardio-Oncology guidelines

These are being developed in consultation with adult and paediatric oncology experts through the Welfi method to attain consensus. Development of these guidelines will reduce individual decisions and promote implementation of standardised protocolised treatment approaches. Ben will be working on this in 2022.

## Register your interest to be part of ACOR

If you are interested or know someone who is interested in being a participating site please contact:

**ACOR National Coordinator via email at [acor@mcri.edu.au](mailto:acor@mcri.edu.au)**

**Or via telephone on: 03 9936 6033**

**We look forward to hearing from you.**